The use of integrase inhibitors in treatment-experienced patients

European Journal of Medical Research

Volumn 14, Issue SUPPL.3, 2009, Pages 30-35

  Gatell, Jose M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE INHIBITOR;

ANTIVIRAL RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; SALVAGE THERAPY;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; SALVAGE THERAPY;

EID: 77951226574     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-14-S3-30     Document Type: Article

References (38)

1. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. JAMA 2008 300 5 555 570 10.1001/jama.300.5.555 18677028
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. N Engl J Med 1998 338 853 860 10.1056/NEJM199803263381301 9516219 (Pubitemid 28135961)
3. Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis. Arribas JR, Pozniak AL, Gallant JE, DeJesus E, Gazzard B, Campo RE, et al. J Acquir Immune Defic Syndr 2008 47 1 74 78 10.1097/QAI.0b013e31815acab8 17971715 (Pubitemid 351619372)
4. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Gupta R, Hill A, Sawyer AW, Pillay D, Clin Infect Dis 2008 47 5 712 722 10.1086/590943 18662137
5. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Clin Infect Dis 2008
6. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. N Engl J Med 2003 348 22 2186 2195 10.1056/NEJMoa035211 12773645 (Pubitemid 36618129)
7. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Temesgen Z, Feinberg J, Clin Infect Dis 2007 45 6 761 769 10.1086/520847 17712762 (Pubitemid 47381280)
8. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Lancet 2006 368 9534 466 475 10.1016/S0140-6736(06)69154-X 16890833 (Pubitemid 44142769)
9. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Lancet 2007 369 9568 1169 1178 10.1016/S0140-6736(07)60497-8 17416261 (Pubitemid 46541620)
10. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, doubleblind, placebo-controlled trial. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Lancet 2007 370 9581 39 48 10.1016/S0140-6736(07) 61048-4 17617271 (Pubitemid 47017467)
11. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Lancet 2007 370 9581 29 38 10.1016/S0140-6736(07)61047-2 17617270 (Pubitemid 47017466)
12. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. Cohen CJ, Berger DS, Blick G, Grossman HA, Jayaweera DT, Shalit P, et al. AIDS 2008
13. DUET-1: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. Haubrich R, Cahn P, Grinsztein B, Lalezari J, Madruga J, Mills A, et al. 15th Conference on Retroviruses and Opportunistic Infections 2008
14. Raltegravir with optimized background therapy for resistant HIV-1 infection. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. N Engl J Med 2008 359 4 339 354 10.1056/NEJMoa0708975 18650512
15. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. N Engl J Med 2008 359 4 355 365 10.1056/NEJMoa0708978 18650513
16. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. J Antimicrob Chemother 2008
17. Maraviroc for previously treated patients with R5 HIV-1 infection. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, HORBAN A, et al. N Engl J Med 2008 359 14 1429 1441 10.1056/NEJMoa0803152 18832244
18. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, THOMPSON MA, Walmsley S, et al. JAMA 2008 300 5 555 570 10.1001/jama.300.5.555 18677028
19. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. Saag M, Goodrich J, Fatkenheuer G, Clotet B, Clumeck N, Sullivan J, et al. J Infect Dis 2009 199 11 1638 1647 10.1086/598965 19432546
20. Raltegravir with optimized background therapy for resistant HIV-1 infection. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. N Engl J Med 2008 359 4 339 354 10.1056/NEJMoa0708975 18650512
21. Raltegravir: The First HIV Type 1 Integrase Inhibitor. Hicks C, Gulick RM, Clin Infect Dis 2009
22. Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics. Iwamoto M, Hanley WD, Petry AS, Friedman EJ, Kost JT, Breidinger SA, et al. Antimicrob Agents Chemother 2009
23. Effect of Rifampin, a Potent Inducer of Drug Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, et al. Antimicrob Agents Chemother 2009
24. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Lancet 2007 369 9569 1261 1269 10.1016/S0140-6736(07)60597-2 17434401 (Pubitemid 46553846)
25. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, et al. J Acquir Immune Defic Syndr 2009
26. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Lancet 2007 369 1261 1269 10.1016/S0140-6736(07)60597-2 17434401 (Pubitemid 46553846)
27. Raltegravir with optimized background therapy for resistant HIV-1 infection. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. N Engl J Med 2008 359 4 339 354 10.1056/NEJMoa0708975 18650512
28. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. N Engl J Med 2008 359 355 365 10.1056/NEJMoa0708978 18650513
29. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 phase III trials. Steigbigel R, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Clin Infect Dis 2009
30. Efficacy and safety of raltegravir plus etravirine and darunavir/ritonavir in treatment experienced patients with multidrug resistant virus: 48 weeks results from the ARNS 139 TRIO trial. 5th IAS. Fagard C, Descamps D, Dubar V, Colin C, Taburet AM, Roquebert B, Cape Town 2009
31. Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection. Imaz A, Del Saz SV, Ribas MA, Curran A, Caballero E, Falco V, et al. J Acquir Immune Defic Syndr 2009
32. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Harris M, Larsen G, Montaner JS, AIDS 2008 22 10 1224 1226 10.1097/QAD.0b013e328302f3b5 18525270
33. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M, J Acquir Immune Defic Syndr 2009 51 4 367 373 10.1097/QAI.0b013e3181ae35de 19487951
34. Switching from stable lopinavir/ritonavir based to raltegravir based combination antiretroviral therapy resulted in superior lipid profile at week 12 but did not demonstrate non-inferior efficacy at week 24. 16th Conference on Retrovirus Opportunistic Infections. Eron J, Andrade JMJ, Zajdenverg R, Workman J, Cooper D, Young B, Montreal 2009
35. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Proc Natl Acad Sci USA 2009 106 23 9403 9408 10.1073/pnas.0903107106 19470482
36. Antiretroviral intensification does not reduce persistent HIV viremia on therapy. XIII International Drug Resistance Workshop. Dinoso JB, Jones J, McMahon D, Fort Myers, Florida 2009
37. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, et al. J Virol 2006 80 13 6441 6457 10.1128/JVI.00591-06 16775332 (Pubitemid 43927447)
38. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. N Engl J Med 2008 359 4 355 365 10.1056/NEJMoa0708978 18650513